KEYTRUDA
-
KEYTRUDA Plus WELIREG Combination Adjuvant Therapy Shows 28% Reduced Risk of Recurrence or Death in Early-Stage Kidney Cancer
Merck’s new adjuvant therapy combining KEYTRUDA and WELIREG shows a 28% reduced risk of recurrence or death in early-stage kidney cancer patients. This promising data could significantly expand the use of Merck’s key oncology drugs, potentially reshaping the competitive landscape in the lucrative kidney cancer market. Analysts are scrutinizing long-term data and market implications.
-
KEYTRUDA® Plus LENVIMA® Shows Durable 5-Year Survival Benefit vs. Chemotherapy in Advanced Endometrial Carcinoma After Prior Platinum Therapy
Merck and Eisai announced five-year follow-up data from the Phase 3 KEYNOTE-775/Study 309 trial, demonstrating a sustained survival benefit of KEYTRUDA plus LENVIMA compared to chemotherapy in patients with advanced endometrial carcinoma. For pMMR patients, the five-year OS rate was 16.7% for the combination versus 7.3% for chemotherapy. These long-term results offer a promising treatment option for this aggressive cancer, despite the associated adverse events. The combination is approved in the U.S., EU, and Japan for specific patients.
-
KEYTRUDA® and Padcev® Combination Improves Survival and Response in Muscle-Invasive Bladder Cancer
Merck’s KEYNOTE-905 (EV-303) trial showed positive results for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy. The study combined KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) before and after surgery, demonstrating statistically significant and clinically meaningful improvement in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) compared to surgery alone. This represents the first systemic therapy to improve survival in this population, potentially establishing a new standard of care. The treatment’s safety profile was consistent with existing data.
-
IO Biotech to Release Topline Phase 3 Melanoma Trial Results for Cylembio® plus KEYTRUDA®
IO Biotech (IOBT) will release topline results from its Phase 3 trial (IOB-013/KN-D18) of Cylembio, an immune-modulatory cancer vaccine, in combination with KEYTRUDA® for advanced melanoma on August 11, 2025. A conference call and live webcast will detail the data comparing Cylembio plus KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment. The trial focuses on patients with unresectable or metastatic melanoma. A replay will be available on the company website.
